Farmacovigilancia de vacunas y su aplicación en Chile

Saldaña, Adiela; Rodríguez, María Pilar; Roldán, Juan; Lobos, Carmen; González, Cecilia; Avendaño, Marcela; Villena, Rodolfo; González, Marcela; Kartzow, Rodrigo Vásquez de; Vergara, Nahum

doi:10.1016/j.rmclc.2020.03.004

Cited by 2 publications

(1 citation statement)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In Australia, healthcare professionals are mandated to report medicine or vaccine events either online or by utilizing a downloadable template [ 106 ]. Chile, which joined the Pharmacovigilance Program initiated by the WHO and the Uppsala Monitoring Center (UMC) in 1972, implemented pharmacovigilance for SARS-CoV-2 in December 2020 [ 121 ]. This effort involves monitoring patients and potential reactions following COVID-19 vaccination.…”

Section: Pharmacovigilancementioning

confidence: 99%

Pharmacovigilance in Vaccines: Importance, Main Aspects, Perspectives, and Challenges—A Narrative Review

Hodel,

Fiuza,

Conceição

et al. 2024

Pharmaceuticals

View full text Add to dashboard Cite

Pharmacovigilance plays a central role in safeguarding public health by continuously monitoring the safety of vaccines, being critical in a climate of vaccine hesitancy, where public trust is paramount. Pharmacovigilance strategies employed to gather information on adverse events following immunization (AEFIs) include pre-registration data, media reports, clinical trials, and societal reporting. Early detection of AEFIs during clinical trials is crucial for thorough safety analysis and preventing serious reactions once vaccines are deployed. This review highlights the importance of societal reporting, encompassing contributions from community members, healthcare workers, and pharmaceutical companies. Technological advancements such as quick response (QR) codes can facilitate prompt AEFI reporting. While vaccines are demonstrably safe, the possibility of adverse events necessitates continuous post-marketing surveillance. However, underreporting remains a challenge, underscoring the critical role of public engagement in pharmacovigilance. This narrative review comprehensively examines and synthesizes key aspects of virus vaccine pharmacovigilance, with special considerations for specific population groups. We explore applicable legislation, the spectrum of AEFIs associated with major vaccines, and the unique challenges and perspectives surrounding pharmacovigilance in this domain.

show abstract

Section: Pharmacovigilancementioning

confidence: 99%